Sino Biopharmaceutical Limited provided group earnings guidance for the year ended 31 December 2021. The board of directors of the company informed the securities holders of the company and potential investors that the Group's profit attributable to the owners of the parent for the year ended 31 December 2021 is expected to increase by over 4 folds as compared to last year to more than approximately RMB 14,000 million (profit attributable to the owners of the parent for last year was RMB 2,771 million).
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.86 HKD | +5.93% | +10.85% | -17.58% |
Apr. 30 | Wall Street, Earnings, Federal Reserve Roil Asian Stock Markets | MT |
Apr. 30 | Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Unecritinib Fumarate Capsules | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.58% | 6.33B | |
+33.25% | 699B | |
+28.59% | 571B | |
-3.55% | 364B | |
+18.16% | 326B | |
+4.36% | 286B | |
+14.81% | 236B | |
+4.93% | 198B | |
-9.78% | 194B | |
-3.69% | 149B |
- Stock Market
- Equities
- 1177 Stock
- News Sino Biopharmaceutical Limited
- Sino Biopharmaceutical Limited Provides Group Earnings Guidance for the Year Ended 31 December 2021